- Home
- LYEL vs MXCT Comparison
LYEL vs MXCT Comparison
Compare LYEL & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- MXCT
- Stock Information
- Founded
- LYEL 2018
- MXCT 1999
- Country
- LYEL United States
- MXCT United States
- Employees
- LYEL N/A
- MXCT N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- LYEL Health Care
- MXCT Health Care
- Exchange
- LYEL Nasdaq
- MXCT Nasdaq
- Market Cap
- LYEL 207.7M
- MXCT 239.2M
- IPO Year
- LYEL 2021
- MXCT 2021
- Fundamental
- Price
- LYEL $7.99
- MXCT $2.28
- Analyst Decision
- LYEL Sell
- MXCT Strong Buy
- Analyst Count
- LYEL 2
- MXCT 1
- Target Price
- LYEL $1.00
- MXCT $9.00
- AVG Volume (30 Days)
- LYEL 52.5K
- MXCT 1.3M
- Earning Date
- LYEL 05-13-2025
- MXCT 05-07-2025
- Dividend Yield
- LYEL N/A
- MXCT N/A
- EPS Growth
- LYEL N/A
- MXCT N/A
- EPS
- LYEL N/A
- MXCT N/A
- Revenue
- LYEL $65,000.00
- MXCT $37,675,000.00
- Revenue This Year
- LYEL N/A
- MXCT $8.82
- Revenue Next Year
- LYEL N/A
- MXCT $21.12
- P/E Ratio
- LYEL N/A
- MXCT N/A
- Revenue Growth
- LYEL N/A
- MXCT N/A
- 52 Week Low
- LYEL $7.65
- MXCT $2.10
- 52 Week High
- LYEL $56.00
- MXCT $5.26
- Technical
- Relative Strength Index (RSI)
- LYEL 42.95
- MXCT 43.19
- Support Level
- LYEL $7.65
- MXCT $2.18
- Resistance Level
- LYEL $10.30
- MXCT $2.40
- Average True Range (ATR)
- LYEL 0.75
- MXCT 0.12
- MACD
- LYEL 0.06
- MXCT 0.02
- Stochastic Oscillator
- LYEL 12.83
- MXCT 60.00
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.